Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to an aqueous eye drop which is administered once a day, comprising an anti-inflammatory 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt thereof or a hydrate thereof as an active ingredient, and having a promoted intraocular penetration and a prolonged retention time of a concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid penetrated into the anterior aqueous humor.
• the present invention also relates to a method for promoting an intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt thereof or a hydrate thereof, and prolonging a retention time of a concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid penetrated into the anterior aqueous humor, characterized in that an organic amine or its salt is combined with an aqueous eye drop comprising, as an active ingredient, 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof.
• 2-Amino-3-(4-bromobenzoyl)phenylacetic acid (generic name: bromfenac) is a compound represented by the following formula (I) and is an acidic non-steroidal anti-inflammatory agent.
• 2-Amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof is effective for inflammatory diseases of the external segment and the anterior segment of the eyes (for example, uveitis, blepharitis, conjunctivitis, scleritis, and postoperative inflammation, etc.).
• inflammatory diseases of the external segment and the anterior segment of the eyes for example, uveitis, blepharitis, conjunctivitis, scleritis, and postoperative inflammation, etc.
• efficacy of such compound for treating uveitis is comparable with steroidal anti-inflammatory agents which have been conventionally used therefor (JP-2-124817-A (U.S. Pat. No. 2,683,676)).
• 2-Amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof has been put into practical use in the form of an eye drop as sodium salt and 3/2 hydrate in the field of ophthalmology.
• examples of medicaments having improvement in absorption promotion into an ocular tissue or intraocular retention include, for example, the followings: H. Sasaki et al., Pharmaceutical Research, 1995, vol. 2, no. 8, p.1146-1150, discloses that corneal permeability of ⁇ -blockers such as atenolol, carteolol, tilisolol, and timolol was accelerated by capric acid in an in vitro experiment; WO 99/22715 discloses that a C 3 -C 7 fatty acid prolonged a retention time of ⁇ -blocker in the ocular tissue; and JP-A-63-301822 (U.S. Pat. No.
• 2,563,3366 discloses that a combination of caproic acid, caprylic acid, and capric acid improved corneal permeability of bunazosin hydrochloride which is an ⁇ 1 adrenergic receptor blocker.
• benzalkonium chloride used as antiseptic in an eye drop promotes not only corneal permeability of tilisolol and FITC (fluorescein isothiocyanate)-dextran but also conjunctival permeability thereof slightly in H. Sasaki et al., Journal of Pharmacy and Pharmacology, 1995, vol.47, no.9, p.703-707).
• an organic amine such as trometamol and the like is used as a buffer in the field of ophthalmology.
• the organic amine such as trometamol and the like is used for stabilization, solubilization, reduction of irritation, and improvement of antiseptic effect in an eye drop.
• a method for inhibiting irritation of the eye due to pranoprofen by combination of an eye drop containing pranoprofen with tromethamine or 4-(2-hydroxyethyl)-1-(2-sulfoethyl)piperazine (see JP-A-8-291065 (U.S. Pat. No. 3,170,619)).
• a method for improving antiseptic effect of sulfa drugs solubilization and by combination of an eye drop containing a sulfa drug with an alkanolamine such as monoethanolamine, diethanolamine, and triethanolamine, followed by dissolution see JP-B-1-29170; JP-A-59-89616; JP-A-61-12617.
• an alkanolamine such as monoethanolamine, diethanolamine, and triethanolamine
• An object of the present invention is to provide an aqueous eye drop which is administered once a day, comprising, as an active ingredient, an anti-inflammatory 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt thereof or a hydrate thereof and having a promoted intraocular penetration and a prolonged retention time of an effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid penetrated into the anterior aqueous humor for treating inflammatory diseases.
• an aqueous eye drop which is obtained by combination of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof with an organic amine or a salt thereof, is administered once a day, thereby to promote the penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid into the ocular tissue and retain a therapeutically effective concentration of said compound in the anterior aqueous humor over a period of at least 24 hours after the administration.
• the present inventors have achieved the completion of the present invention.
• the present invention provides the following methods:
• a method for treating inflammatory diseases of the external segment or the anterior segment of the eyes which comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof once a day, and maintaining a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor at least for 24 hours after the administration,
• the aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, and the content of the aforementioned organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4,
• the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid,
• a method for promoting intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof which comprises administering an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof comprises an organic amine or a salt thereof, wherein the content of said organic amine or salt thereof is an amount to allow the octanol-water partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be 0.7 to 4.
• the present invention provides the following inventions:
• an aqueous eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes characterized in that a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof is maintained in the anterior aqueous humor for at least 24 hours by once a day administration,
• the organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid,
• organic amine is an aminoalkylsulfonic acid and its concentration is 0.05 to 5 w/v %
• an aqueous eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes characterized in that a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is maintained in the anterior aqueous humor for at least 24 hours by once a day administration of 0.01 to 0.5 w/v % 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and 0.05 to 5 w/v % aminoethylsulfonic acid.
• organic amine is at least one member selected from the group consisting of an amino acid, an alkanolamine, a diamine, a piperazine, and an aminoalkylsulfonic acid,
• the aqueous eye drop of the present invention is only administered once a day, thereby to be able to retain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor for at least 24 hours after the administration.
• an aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, wherein an organic amine or its salt is combined to thereby promote intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof after administration of the eye drop, and retain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid for treating inflammatory diseases.
• the aqueous eye drop of the present invention can be advantageously used for treating, for example, uveitis, blepharitis, conjunctivitis, scleritis, postoperative inflammation or the like in the form of an eye drop which is administered once a day.
• Examples of pharmacologically acceptable salts of 2-amino-3-(4-bromobenzoyl)phenylacetic acid used in the aqueous eye drop of the present invention include, though not particularly limited, for example, an alkali metal salt such as sodium salt and potassium salt, an alkaline earth metal salt such as calcium salt and magnesium salt, and the like. Among these salts, a sodium salt is particularly preferable.
• 2-Amino-3-(4-bromobenzoyl)phenylacetic acid and its pharmacologically acceptable salt can be produced appropriately by the method according to JP-A-52-23052 (corresponding to U.S. Pat. No. 4,045,576) or its similar method.
• hydrates thereof are obtained as hydrates thereof depending on the conditions such as synthesis and recrystallization.
• examples of such hydrates include, though not particularly limited, for example, hemihydrates, monohydrates, and 3/2 hydrates, etc., among which 3/2 hydrates is particularly preferable.
• the content (concentration range) of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrates is usually about 0.01 w/v % to 0.5 w/v %, preferably about 0.05 w/v % to 0.2 w/v %, particularly preferably about 0.1 w/v % to 0.2 w/v %. It is preferable to adjust the content appropriately according to the intended purpose and the degree of diseases to be treated.
• an organic amine or its salt can be used in order to promote the penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof into the ocular tissue and to retain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid, which has been penetrated into the anterior chamber, in the anterior aqueous humor for at least 24 hours after the intraocular administration.
• OECD Test Guideline 107 (adopted by the OECD Council “C (81) 30 Annex 1”) or Japanese Industrial Standard Z7260-107(2000)“Partition coefficient (1-octanol/water)-Shake flask method” and, to be more specific, such coefficient can be measured by the test method of Experimental Example 3 as described below.
• organic amine or a salt thereof preferred are those which are able to adjust a partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to about 0.7 to 4 in the test method of Experimental Example 3 (Measurement of Octanol-Water Partition Coefficient) as described below.
• organic amines or salts thereof include, for example, amino acids (e.g. arginine, histidine, aspartic acid, glutamic acid, serine, threonine, cysteine, phenylalanine, isoleucine, etc.), alkanolamines (e.g.
• piperazines e.g. HEPES (2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid), 1,4-bis(2-sulfoethyl)piperazine, etc.
• diamines e.g. ethylene diamine, trimethylene diamine, N,N′-bis(3-sulfopropyl)ethylene diamine, etc.
• aminoalkylsulfonic acids e.g. aminomethylsulfonic acid, aminoethylsulfonic acid, etc.
• an alkanolamine or an aminoalkylsulfonic acid is preferable, and particularly preferred is aminoethylsulfonic acid or trometamol.
• salts of an organic amine include inorganic acid salts (e.g. hydrochloride, nitrate, sulfate, sulfite, phosphate, or hydroiodide, etc.), organic acid salts (e.g. acetate, formate, oxalate, lactate, gluconate, adipate, or alkyl phosphate, etc.), inorganic base salts (e.g. sodium salt, calcium salt, magnesium salt, etc.), and organic base salts (e.g. ammonium salt, etc.).
• inorganic acid salts e.g. hydrochloride, nitrate, sulfate, sulfite, phosphate, or hydroiodide, etc.
• organic acid salts e.g. acetate, formate, oxalate, lactate, gluconate, adipate, or alkyl phosphate, etc.
• inorganic base salts e.g. sodium salt, calcium
• organic amines or salts thereof may be used solely or in combination of two or more salts.
• the content (concentration range) of an organic amine or its salt is in the concentration range which allows a partition coefficient of 2-amino-3-(4-bromobenzoyl)phenylacetic acid to be about 0.7 to 4 in the test method of Experimental Example 3 (Measurement of Octanol-Water Partition Coefficient) as described below.
• concentration range is different depending on a kind of the compound used and the like, the lower limit is usually about 0.01 w/v % and the upper limit is about 5.0 w/v %.
• the lower limit of the content is about 0.35 w/v %, preferably about 0.4 w/v %, and the upper limit of the content is about 5 w/v %, preferably about 2 w/v %.
• the lower limit of the content is about 0.15 w/v %, preferably about 0.2 w/v %, and the upper limit of the content is about 0.95 w/v %, preferably about 0.9 w/v %.
• the lower limit of the content is about 0.05 w/v %, preferably about 0.1 w/v %, and the upper limit of the content is about 5 w/v %, preferably about 2 w/v %.
• the lower limit of the content is about 0.05 w/v %, preferably about 0.1 w/v%, and the upper limit of the content is about 5 w/v %, preferably about 2 w/v %.
• the lower limit of the content is about 0.05 w/v %, preferably about 0.1 w/v %, and the upper limit of the content is about 5 w/v %, preferably about 2 w/v %, more preferably about 1 w/v %.
• the lower limit of the content is about 0.05 w/v %, preferably about 0.1 w/v %, and the upper limit of the content is about 5 w/v %, preferably about 2 w/v %, more preferably about 1 w/v %.
• the lower limit of the content is about 0.15 w/v %, preferably about 0.2 w/v %, and the upper limit of the content is about 0.95 w/v %, preferably about 0.9 w/v %.
• the aqueous eye drop of the present invention is usually adjusted to the pH of about 5.0 to 9.0, preferably about 6.5 to 8.5, more preferably about 7.0 to 8.0.
• an additive usually used for eye drops including, for example, isotonic agents (e.g. sodium chloride, potassium chloride, glycerin, concentrated glycerin, mannitol, sorbitol, boric acid, glucose, and propylene glycol, etc.), buffers (e.g. phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamic acid, and ⁇ -aminocaproic acid, etc.), water-soluble polymers (e.g.
• isotonic agents e.g. sodium chloride, potassium chloride, glycerin, concentrated glycerin, mannitol, sorbitol, boric acid, glucose, and propylene glycol, etc.
• buffers e.g. phosphate buffer, acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, glutamic acid, and ⁇ -aminocaproic acid, etc.
• water-soluble polymers
• povidones povidone K30 and povidone K25, etc.
• polyvinyl alcohol and sodium polyacrylate, etc.
• surfactants e.g. alkyl aryl polyether alcohol type polymers (e.g. tyloxapol, etc.), polyethylene glycol fatty acid esters (e.g. polyethylene glycol monostearate, etc.), polysorbate 80, polyoxyethylene hydrogenated caster oil, etc.
• preservatives e.g.
• benzalkonium chloride benzethonium chloride, chlorhexidine gluconate, chlorobutanol, benzyl alcohol, sodium dehydroacetate, parahydoxybenzoic acid esters, disodium edetate, and boric acid, etc.
• stabilizers e.g. sodiumbisulfite, sodium thiosulfate, disodiumedetate, sodium citrate, ascorbic acid, and dibutylhydroxytoluene, etc.
• the amount of the additive may, though it is different depending on the kind and use, etc. of the additive to be added, be a concentration capable of accomplishing the intended use thereof.
• the isotonic agent can be usually added in an amount so as to give an osmotic pressure ratio of about 0.8 to 1.2.
• the buffer is added in an amount of about 0.01 to 2 w/v %
• the water-soluble polymer is added in an amount of about 0.1 to 10 w/v %
• the surfactant is added in an amount of about 0.01 to 0.5 w/v %
• the preservatives is added in an amount of about 0.0005 to 0.5 w/v %
• the stabilizer is added in an amount of about 0.001 to 1 w/v %.
• Examples of the same kind of active ingredients include, though not limited thereto, for example, pranoprofen, fluorometholone, prednisolone acetate, dexamethasone, and sodium azulene sulfonate, etc.
• Examples of the different kind of active ingredients include, for example, antimicrobial ingredients (e.g.
• ketotifen fumarate sodium cromoglycate, levocabastine hydrochloride, pemirolast potassium, chlorpheniramine maleate, ibudilast, and diclofenac sodium, etc.
• active ingredients for treating corneal diseases e.g. hyaluronic acid and salts thereof, etc.
• antiglaucomaingredients e.g.
• the aqueous eye drop of the present invention can be produced according to the known method, for example, the method as described in Japanese Pharmacopoeia Fourteenth Edition, General Rules for Preparations, for example, the method by dissolving the above ingredients in an aqueous medium.
• aqueous medium used include, for example, purified water, water for injection, and sterile purified water, etc.
• the aqueous eye drop of the present invention can also be provided as an eye drop without no preservative (disposable type).
• a single dose thereof is preferably stored in a tightly sealed container which can be opened at the time of use.
• the aqueous eye drop of the present invention is a disposable eye drop, there can be produced an eye drop which has no fear of contamination by microbes even if preservatives are not contained therein.
• the present invention provides a method for prolonging a retention time of a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the ocular tissue, particularly, in the anterior chamber or anterior ocular segment, characterized by intraocular administration of the above aqueous eye drop.
• the therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid according to the present invention means a concentration at which an intraocular inflammation after anterior chamber puncture in rabbits can be inhibited by at least not less than about 25% as shown in Experimental Example 2 (Medicinal Efficacy Test in a Rabbit Model of Anterior Chamber Puncture) described below.
• the concentration at which the intraocular inflammation can be inhibited by at least not less than about 25% after anterior chamber puncture in rabbits is not less than about 1.5 ng/mL.
• the concentration of said medicament in the anterior chamber can be measured by the HPLC method for the anterior aqueous humor collected through anterior chamber puncture, as shown in Experimental Example 1 (Penetration Test of a Medicament in the Aqueous Humor) described below.
• the aqueous eye drop of the present invention can prolong a retention time of therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the ocular tissue, particularly, in the anterior chamber or anterior ocular segment.
• the said prolongation of the retention time of the therapeutically effective concentration means that the retention time of the therapeutically effective concentration in the aqueous humor can last more than about 12 hours, preferably at least about 24 hours in the case where an eye drop containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a salt thereof is administered once.
• aqueous eye drop of the present invention can retain the therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid for at least 24 hours after intraocular administration in the ocular tissue or anterior ocular segment, administration frequency of said aqueous eye drop can be once a day.
• the doses of the aqueous eye drop of the present invention may be one to several (2 to 5) drops, and the dose frequency of said aqueous eye drop can be once a day for adults, for example, in the case where the eye drop of the present invention containing 0.1 w/v % of 2-amino-3-(4-bromobenzoyl)phenylacetic acid 3/2 hydrate is used for treating blepharitis, conjunctivitis, scleritis, postoperative inflammation, or uveitis, etc.
• the dose frequency of the eye drop can be appropriately increased or decreased depending on the symptom.
• Formulation Formulation Component 1 2 3 Sodium 2-amino-3-(4- 0.1 g 0.1 g 0.1 g bromobenzoyl)phenyl acetate 3/2 hydrate Boric acid 1.8 g — — Trometamol — 0.5 g — Aminoethylsulfonic — — 0.2 g acid Concentrated glycerin — 2.0 g 2.4 g Sodium hydroxide q.s. — q.s. Hydrochloric acid — q.s. — Purified water q.s. q.s. q.s. Total amount 100 mL 100 mL 100 mL pH 7.8 7.8 7.8 2. Test Method
• the rabbits were euthanized by overdosing a solution of pentbarbital sodium 2 hours after the intraocular administration.
• the aqueous humor was collected by using a syringe with a 27G injection needle.
• 160 ⁇ L of the collected aqueous humor was mixed with 160 ⁇ L of a mobile phase for pretreatment/concentration as mentioned below, and then the mixture was filtered with a membrane filter (0.45 ⁇ m).
• the filtrate was served as a sample of HPLC measurement and then the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid was determined under the HPLC condition mentioned below by using High Performance Liquid Chromatograph (Shiseido Co., Ltd., type: Nanospace SI-1).
• the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the aqueous humor was 214 ⁇ 46 (ng/mL) 2 hours after the intraocular administration.
• concentrations of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the aqueous humor were respectively 260 ⁇ 45 (ng/mL) and 350 ⁇ 123 (ng/mL) 2 hours after the intraocular administration (Table 3).
• the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the aqueous humor 2 hours after the intraocular administration increased about 1.2 times in case of the formulation containing trometamol and about 1.6 times in case of the formulation containing aminoethylsufonic acid compared to the eye drop of Formulation 1.
• TABLE 3 2-Amino-3-(4-bromobenzoyl)phenylacetic acid (ng/mL) Formulation 1 214 ⁇ 46 Formulation 2 260 ⁇ 45 Formulation 3 350 ⁇ 123
• heparin sodium injection (Heparin sodium injection, Ajinomoto Co., Inc.) was administered into the rabbit's ear vein.
• a disposable intraocular injection needle (30G ⁇ 3 ⁇ 4, Nipro Medical Industries, Ltd.) was curvedly punctured from the corneal center side at the position which is about 1 mm apart from the 1 o'clock position of rabbit's eyeball limbus to collect 80 ⁇ L of the anterior aqueous humor via the cornea (puncture of anterior chamber).
• the flare value (photon count/msec) in the anterior chamber was determined 30 minutes after the puncture of anterior chamber using a laser flare cell meter (FC-1000, Kowa Company, Ltd.). 50 ⁇ L of the test material was administered 24 hours before the puncture of anterior chamber. Meanwhile, nothing was administered to the control group.
• Inhibition rate (%) ((Average flare value in the anterior chamber of the control group) minus (Average flare value in the anterior chamber of the test material administered group))/(Average flare value in the anterior chamber of the control group) ⁇ 100 4 .
• Table 5 shows the inhibition rate of inflammation after the puncture of anterior chamber, which was calculated by the measured flare value in the anterior chamber.
• the inhibition rate of the formulation in which no aminosulfonic acid was added (Formulation 4) was 0.3% at 24 hours after the puncture.
• the inhibition rate of Formulation 5 was 25.5% and the inhibition rate of Formulation 6 was 73.9%, both of the formulations being combined with aminoethylsulfonic acid.
• the concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in each phase was determined by high performance liquid chromatography (Shimadzu Co., type:LC-10AD).
• LC-10AD high performance liquid chromatography
• As a control there was used a solution of only sodium 2-amino-3-(4-bromobenzoyl)phenylacetate 3/2 hydrate dissolved in 10 mM sodium dihydrogenphosphate dihydrate buffer (pH 7.8) so as to be 0.1 w/v %.
• Octanol-water partition coefficient (Concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the octanol phase)/(Concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the aqueous phase) 4.
• the above components were mixed to prepare an aqueous eye drop.
• the above components were mixed to prepare an aqueous eye drop.
• the above components were mixed to prepare an aqueous eye drop.
• the above components were mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• the above components are mixed to prepare a disposable aqueous eye drop.
• the above components are mixed to prepare an aqueous eye drop.
• an aqueous eye drop which can promote an intraocular penetration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt thereof or a hydrate thereof and can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in the anterior aqueous humor for at least 24 hours for treating inflammatory diseases after the intraocular administration, characterized in that an organic amine or its salt is combined with an aqueous eye drop comprising, as an active ingredient, 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof.
• the aqueous eye drop of the present invention is advantageously used for treating blepharitis, conjunctivas, scleritis, postoperative inflammation, anduveitis, etc. in the form of an eye drop which is administered once a day.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Immunology (AREA)
• Ophthalmology & Optometry (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=36319250

Family Applications (3)

Family Applications After (2)

Country Status (11)

Cited By (7)

Families Citing this family (6)

Citations (11)

Family Cites Families (12)

• 2005
  • 2005-11-04 PL PL05805529T patent/PL1808170T3/pl unknown
  • 2005-11-04 WO PCT/JP2005/020302 patent/WO2006049250A1/ja active Application Filing
  • 2005-11-04 KR KR1020137015731A patent/KR20130080061A/ko not_active Application Discontinuation
  • 2005-11-04 JP JP2006542445A patent/JP4933897B2/ja not_active Expired - Fee Related
  • 2005-11-04 ES ES05805529T patent/ES2369089T3/es active Active
  • 2005-11-04 KR KR1020067022310A patent/KR101312740B1/ko active IP Right Grant
  • 2005-11-04 EP EP05805529A patent/EP1808170B1/en not_active Not-in-force
  • 2005-11-04 AT AT05805529T patent/ATE520394T1/de active
  • 2005-11-04 CN CN2005800259636A patent/CN1993118B/zh not_active Expired - Fee Related
  • 2005-11-04 US US10/568,418 patent/US20070021507A1/en not_active Abandoned
  • 2005-11-04 MX MX2007001172A patent/MX2007001172A/es active IP Right Grant
  • 2005-11-04 CA CA2560559A patent/CA2560559C/en not_active Expired - Fee Related
• 2011
  • 2011-12-21 US US13/332,827 patent/US8299124B2/en active Active
• 2012
  • 2012-09-14 US US13/616,810 patent/US8518996B2/en not_active Expired - Fee Related

Patent Citations (12)

Also Published As

Similar Documents

Legal Events